Tiny warriors, big impact: targeted immunotherapy in kidney diseases

Area of Science:

• Immunology
• Nephrology
• Oncology

Background:

• B cell-targeted immunotherapies, including CAR-T cell therapy, are emerging as effective treatments for autoimmune diseases.
• Existing therapies like anti-CD20 antibodies have limitations, and many patients with autoimmune kidney diseases do not respond adequately.

Purpose of the Study:

• To review the kidney-specific applications and side effects of novel immunotherapies targeting B cells.
• To provide a perspective on emerging immunotherapeutic approaches for autoimmune kidney diseases.

Main Methods:

• Review of current literature on CAR-T cells and T cell engagers in autoimmune kidney diseases.
• Analysis of efficacy and safety data from investigator-initiated trials and case series.

Main Results:

• CD19+ CAR-T cells have shown efficacy and safety in therapy-resistant systemic lupus erythematosus (SLE), leading to B cell depletion and clinical remission.
• Autoreactive B cells play a key role in the pathogenesis of various kidney diseases, including lupus nephritis, ANCA-associated vasculitis, membranous nephropathy, and IgA nephropathy.

Conclusions:

• Novel B cell-targeting immunotherapies hold potential for more effective B cell depletion and sustained autoimmunity suppression in kidney diseases.
• Further investigation into renal endpoints like proteinuria reduction, eGFR stabilization, and histological improvements is crucial for these advanced therapies.